356 related articles for article (PubMed ID: 7608256)
1. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects.
Beldjord C; Desclaux-Arramond F; Raffin-Sanson M; Corvol JC; De Keyzer Y; Luton JP; Plouin PF; Bertagna X
J Clin Endocrinol Metab; 1995 Jul; 80(7):2063-8. PubMed ID: 7608256
[TBL] [Abstract][Full Text] [Related]
2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
3. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B.
Maruyama S; Iwashita T; Imai T; Funahashi H; Ceccherini I; Luo Y; Romeo G; Matsuo S; Matsuyama M; Takahashi M
Jpn J Cancer Res; 1994 Sep; 85(9):879-82. PubMed ID: 7961113
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the RET protooncogene in sporadic pheochromocytomas.
Lindor NM; Honchel R; Khosla S; Thibodeau SN
J Clin Endocrinol Metab; 1995 Feb; 80(2):627-9. PubMed ID: 7852530
[TBL] [Abstract][Full Text] [Related]
5. The RET proto-oncogene and cancer.
Donis-Keller H
J Intern Med; 1995 Oct; 238(4):319-25. PubMed ID: 7595167
[TBL] [Abstract][Full Text] [Related]
6. The RET proto-oncogene in sporadic pheochromocytomas.
Takaya K; Yoshimasa T; Arai H; Tamura N; Miyamoto Y; Itoh H; Nakao K
Intern Med; 1996 Jun; 35(6):449-52. PubMed ID: 8835594
[TBL] [Abstract][Full Text] [Related]
7. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK
Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
[TBL] [Abstract][Full Text] [Related]
8. Absence of mutations at codon 768 of the RET proto-oncogene in sporadic and hereditary pheochromocytomas.
Yoshimoto K; Kimura T; Tanaka C; Moritani M; Iwahana H; Itakura M
Endocr J; 1996 Feb; 43(1):109-14. PubMed ID: 8732460
[TBL] [Abstract][Full Text] [Related]
9. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
Pausova Z; Soliman E; Amizuka N; Janicic N; Konrad EM; Arnold A; Goltzman D; Hendy GN
J Clin Endocrinol Metab; 1996 Jul; 81(7):2711-8. PubMed ID: 8675600
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific mutations in the tyrosine kinase domain of the RET proto-oncogene in pheochromocytomas of sporadic type.
Yoshimoto K; Tanaka C; Hamaguchi S; Kimura T; Iwahana H; Miyauchi A; Itakura M
Endocr J; 1995 Apr; 42(2):265-70. PubMed ID: 7627271
[TBL] [Abstract][Full Text] [Related]
11. Frequent RET protooncogene mutations in multiple endocrine neoplasia type 2A.
Quadro L; Panariello L; Salvatore D; Carlomagno F; Del Prete M; Nunziata V; Colantuoni V; Di Giovanni G; Brandi ML; Mannelli M
J Clin Endocrinol Metab; 1994 Aug; 79(2):590-4. PubMed ID: 7913936
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2.
Ponder BA
Cancer Surv; 1995; 25():195-205. PubMed ID: 8718519
[No Abstract] [Full Text] [Related]
13. Absence of mutations in the MEN2A region of the ret proto-oncogene in non-MEN 2A phaeochromocytomas.
Chew SL; Lavender P; Jain A; Weber A; Ross RJ; Wass JA; Besser GM; Clark AJ
Clin Endocrinol (Oxf); 1995 Jan; 42(1):17-21. PubMed ID: 7889627
[TBL] [Abstract][Full Text] [Related]
14. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
Romei C; Elisei R; Pinchera A; Ceccherini I; Molinaro E; Mancusi F; Martino E; Romeo G; Pacini F
J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377
[TBL] [Abstract][Full Text] [Related]
16. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A
Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697
[TBL] [Abstract][Full Text] [Related]
17. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y
Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060
[TBL] [Abstract][Full Text] [Related]
18. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer.
Blaugrund JE; Johns MM; Eby YJ; Ball DW; Baylin SB; Hruban RH; Sidransky D
Hum Mol Genet; 1994 Oct; 3(10):1895-7. PubMed ID: 7849720
[No Abstract] [Full Text] [Related]
19. Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland.
Padberg BC; Schröder S; Jochum W; Kastendieck H; Roth J; Heitz PU; Komminoth P
Am J Pathol; 1995 Dec; 147(6):1600-7. PubMed ID: 7495285
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
Kambouris M; Jackson CE; Feldman GL
Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]